Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 263-092-3 | CAS number: 61789-85-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Remarks:
- other: A four week inhalation toxicity study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Exposures were initiated on 27 October 1986 and were compl eted; on 21 November 1986.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guideline and the study was conducted under GLP conditions.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 987
- Report date:
- 1987
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Sulfonic acids, petroleum, calcium salts
- EC Number:
- 263-093-9
- EC Name:
- Sulfonic acids, petroleum, calcium salts
- Cas Number:
- 61789-86-4
- IUPAC Name:
- 61789-86-4
- Details on test material:
- Details on test material
Sponsor's identification: OS80020 (product as manufactured diluted to 65% in mineral oil)
Description: Brown liquid
Purity: 35% Active Ingredient (contains 65% oil)
Lot No.: Not supplied
Label: Sample 05#80020 Date 10-2-86,
Date received 03 October 1986
Storage conditions: Temperature monitored room (60 - 85°F).
Expiry date: Not supplied
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: CD® (Sprague-Dawley) strain rats were obtained from Charles River Breeding Laboratories, Inc. Kingston, New York 12484.
- Age at study initiation: Approximately 6 (males) to 7 weeks old (females)
- Weight at study initiation: 205 to 232 g (male); 1556 to 186 g (female)
- Fasting period before study: Not applicable
- Housing: Animals were doubly-housed in suspended stainless steel wire mesh cages during the first week of the acclimation period and individually housed during the remainder of the acclimation period and all other non-exposure periods.
- Diet: was available ad libitum standard laboratory diet (Purina® Rodent Laboratory Chow #5001).
- Water: was available ad libitum via an automated watering system (Supplier: Elizabethtown Water Company).
- Acclimation period: Animals were acclimated for approximately two weeks (14 through 27 October 1986). All animals were examined by the staff veterinarian during the acclimation period.
ENVIRONMENTAL CONDITIONS
- Temperature: Monitored and recorded twice daily.
- Specified Ranges: 22 ± 3°C
- Actual range: 21-26 °C
- Humidity (%): Monitored continuously and recorded twice during exposure.
- Specified Ranges: 30 - 70%
- Actual range: 20 - 76%2
In-Life Dates: First day of treatment: 27 October 1986 - Necropsy day was 24 November 1986.
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Remarks on MMAD:
- MMAD / GSD: See attached Appendix B
- Details on inhalation exposure:
- Test; Substance Administration and Chamber Operation (see attached Appendix B)
Route: inhalation, administered in the breathing zone of the animals as a respirable aerosol.
Justification of Route: Inhalation was chosen as the route of administration since it is a potential route of human exposure to this test substance.
Target Exposure Levels: 0 (Control), 50, 150 and 250 milligrams particulate per cubic meter of air (mg/m3).
Frequency of Exposure; Daily (6 hours per day, 5 days per week for 4 weeks).
Chamber Operation: The glass and stainless steel exposure chambers in which the animals were exposed had a total volume of 1000 liters with an effective volume of 760 liters. The airflow rate, time for air change and 99% equilibrium time are summarised as follows:
Group Airflow Air 99% Equilibrium
Rate (1pm) Change (min) Time (min)
I 213 4.7 22
II 215 4.7 21
III 211 4.7 22
IV 210 4.8 22
Exposure Procedure
An appropriate amounts of the test material was placed in an Erlenmeyer flask connected to an FMI fluid metering pump (Model #RPG-6 or RPG~20) with a 1/8" piston and an initial setting of 13, 17 and 20% for Groups II, III and. IV respectively. The test material was delivered from the flask to the inlet, of an air atomizing nozzle (Spraying Systems Co. 1/4" JSS nozzle with an #1A spray regulator (at a constant back-pressure of 20 pounds per square inch, psi} and a Dwyer flow meter via 3/8" Tygon® tubing, to the air inlet of the atomizer to generate the aerosol. The test atmosphere was directed, diluted with room air to the inlet portal of the exposure chamber which housed the animals.
The animals remained in the chamber for 30 minutes following exposure to allow the chamber air to clear using room air only.
Exposure Chamber Sampling and Monitoring:
Samples for gravimetric determinatipn of the OS80020 exposure levels were drawn from the exposure chamber using Whatman glass microfibre filter paper (Type GF/F, 3.7 cm) mounted in a Gelman filter holder. Samples were withdrawn at one and one and a half hour intervals from the normal sampling portal for 20, 20, 5 and 2 minutes at an airflow rate of 10 1pm for Groups I, II, III and IV, respectively.
Particle size Analysis
Particle size. distribution assessments were made once each week using a Delron DCI-6 cascade impactor. The mass median aerodynamic diameter (MMAD) and geometric standard deviation: were calculated based on the amount of material collected on the impactor stages (glass slides). Particle size analysis was not performed for the control group (Group I).
The nominal concentration was determined by weighing the generation apparatus containing the test substance before and after the exposure and dividing the difference in these, weights by the total volume of air delivered during exposure (volumetric flow rate times total exposure time).
An Airguide® Humidity Indicator was used to continuously monitor relative humidity and a Taylor thermometer was used to continuously monitor air temperature in the exposure chamber. Recordings of temperature and relative humidity were made four times during exposure. - Details on analytical verification of doses or concentrations:
- Chamber Monitoring Results (See attached Appendix B):
The test animals received mean gravimetric and nominal exposure concentrations of the test material as follows:
Group Test Test Mean Analytical Nominal
Substance Concentration Concentration Concentration
(mg/m3) (mg/m3) (mg/m3)
I Control 0 0.04 -
II OS80020 50 49.5 272
III OS80020 150 156 1060
IV OS80020 250 260 1360
The average concentration levels, when compared to the target levels, was considered quite acceptable. Also the day to day variability of concentrations was reasonable. The differences between nominal and analytical levels were typical for this experimental design and reflect aerosol deposition on chamber surfaces and animal fur.
Particle size analysis using the Cascade Impactor showed the average mass median diameter of the aerosol to range from 3.3 to 3.7 microns, with an average geometric standard deviation ranging from 2.0 to 2.1 . This data ,indicated that the aerosol was of a respirable size to the rat, with at least 93% of the particles less than 10 microns in diameter. - Duration of treatment / exposure:
- OS80020 was administered by inhalation as an aerosol to 30 CD® (Sprague-Dawley) rats (5/sex/group) for: 6 hours per day, 5 days per week over 4 weeks, at target concentrations of 50, 150 and 250 milligrams aerosol per cubic meter of air (mg/m3). Control animals (5/sex) received air only, while in chamber. Exposures were initiated on 27 October 1986 and were completed on 21 November. 1986.
- Frequency of treatment:
- Once daily (5 days a week) for a six hour dosing period over a 4 week treatment period.
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
Control - five males and five females
Basis:
other: air only
- Remarks:
- Doses / Concentrations:
Group 2 - five males and five females
Basis:
other: 50 milligrams aerosol per cubic meter of air (mg/m3).
- Remarks:
- Doses / Concentrations:
Group 3 - five males and five females
Basis:
other: 150 milligrams aerosol per cubic meter of air (mg/m3).
- Remarks:
- Doses / Concentrations:
Group 4 - five males and five females
Basis:
other: 250 milligrams aerosol per cubic meter of air (mg/m3).
- No. of animals per sex per dose:
- five males and five females per treatment group
- Control animals:
- yes, sham-exposed
- Details on study design:
- Dose selection rationale:
- Based on previoulsy available toxicity information.
Rationale for animal assignment (if not random):
- Random
Rationale for selecting satellite groups:
- Not applicable
Post-exposure recovery period in satellite groups:
- Not applicable
Section schedule rationale (if not random):
- Random - Positive control:
- Not applicable
Examinations
- Observations and examinations performed and frequency:
- - see attached Appendices A to J.
CAGE SIDE OBSERVATIONS:- Mortality, gross signs of toxicological and pharmacological effects were performed twice daily.
- All animals. were, observed for abnormalities as a group (in cage) both during the exposure, and individually following exposure.
- Detailed physical examinations were performed weekly (post-exposure on Test Days 5, 12, 19 and 26). In addition, observations were recorded once during the pre test period.
BODY WEIGHT:
- Weekly (post-exposure on Test Days 5, 12, 19 and 26). In addition, bodyweights were obtained prior to exposure on Test Day 1.
FOOD CONSUMPTION: Not applicable.
- Laboratory diet was supplied ad libitum.
FOOD EFFICIENCY: Not applicable.
WATER CONSUMPTION: Not applicable.
Water was supplied ad libitum via an automated watering system.
OPHTHALMOSCOPIC EXAMINATION: Not applicable.
HAEMATOLOGY AND CLINICAL CHEMISTRY:
Blood was obtained via veni puncture of the orbital sinus immediately prior to sacrifice.
Animals were fasted overnight prior to blood collection.
- Time schedule for collection of blood: Haematological and blood chemical investigations were performed on all five males and five females from each test and control group prior to termination on Day 29.
URINALYSIS: Not applicable.
NEUROBEHAVIOURAL EXAMINATION:- Not applicable.
Behavioural assessment - Not applicable.
Functional Performance Tests - Not applicable.
Sensory Reactivity - Not applicable. - Sacrifice and pathology:
- - see attached Appendix J.
A complete gross postmortem examinations was performed on all animals dying spontaneously as well as on those surviving to study termination. Gross postmortem examinations included examination. of the external surface, all orifices, the cranial cavity, carcass, the external and sectioned 'surfaces of the brain, and spinal cord, nasal cavity and paranasal sinuses, the thoracic, abdominal and pelvic cavities and there viscera and the cervical tissues and organs.
Selected tissues were examined from all control and high dose animals. - Other examinations:
- Not applicable.
- Statistics:
- See atatched appendices E to I.
Bodyweights, haematology, clinical chemistry, terminal organ and body weights and organ/body weight ratios were analysed.
Mean values of all dose groups were compared to control at each time interval and statistically significant differences from control are indicated on mean table and appendices.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Details on results:
- RESULTS AND DISCUSSION:
Chamber Monitoring Results (see attached Appendix B).
The test animals received mean gravimetric and nominal exposure concentrations of the test material. The average concentration levels, when compared to the target levels, was considered quite acceptable. Also the day to day variability of concentrations was reasonable. The differences between nominal and analytical levels were typical for this experimental design and reflect aerosol deposition on chamber surfaces and animal fur.
Particle size analysis using the Cascade Impactor showed the average mass median aerodynamic diameter of the aerosol to range from 3.3 to 3.7 microns, with an average geometric standard deviation ranging from 2.0 to 2.1. This data indicated that the aerosol was of a respirable size to the rat, with at least 93% of the particles less than 10 microns in diameter.
Mortality (see attached Appendix C).
There was no morta1ity associated with test-materia1 exposure. A Group I male escaped from it’s caging after, the 17th exposure and was not located until the day of scheduled sacrifice when the animal was then euthanized. Also, a Group I male died during blood collection immediately prior to its scheduled sacrifice.
Clinical Observations (see attached Appendix D).
- Daily Observations during the Exposure Period:
There appeared to be test material related signs during the exposures, especially at the two higher levels. The signs were first noted after 4 to 5 exposures and consisted of red nasal discharge, matted coat and decreased activity.
- Weekly Observations during the post-exposure period:
The observations included an increased incidence of dried red nasal discharge and matted coat among the treated animals. However, the relation of these signs to exposure level was not clear. There were no significant respiratory signs seen in the test animals.
Body Weights (see attached Appendix E).
Although there were no statistically significant differences seen between control and treated groups, there was clearly a trend towards lower body weight gain in the exposed animals especially in the males at the high level.
Haematology and Clinical Chemistry (see attached Appendix F, G and H).
Several parameters in test groups were statistically different from control. These included increased hematocrit (Group II females), creatine phosphokinase (Group II and IV females) and sodium (Group IV females). However, considering that these differences were scattered throughout only one sex, and generally were small differences, the relation to treatment is questionable.
Terminal Organ and Body Weights and Organ/Body Weight Ratios (see attached Appendix I).
In both sexes, a clear dose-related trend was seen in both increased lung weights and lung ratios affecting the two higher levels. The increases were statistically significant in Group III and IV lung ratios (both sexes), Group IV lung weights (both sexes) and Group III lung weights (males).
The other organ weights and ratios were unremarkable.
Gross and Microscopic Pathology (see attached Appendix J).
A few grossly visible changes were noted. They appeared sporadic and were not considered to be related to the test article.
Microscopically, a higher incidence of accumulations of intra alveolar macrophages and hyperplasia/hypertrophy of bronchiole epithelium was seen in the lungs of the treated animals when compared to the control animals. These changes were clearly dose-related at the two higher levels, but were equivocal at the lower level. Other microscopic findings in the lungs and other tissues did not appear to be related to the test article.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/m³ air
- Based on:
- test mat.
- Remarks:
- Product as manufactured in mineral oil solvent further diluted in mineral oil (65/35)
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The repeated inhalation exposure of OS80020 (product as manufactured diluted to 65% in mineral oil) by aerosol atmospheres for a period of twenty-eight consecutive days at target concentrations of 50, 150 and 250 mg/m3 produced treatment-related changes at all dose levels and on this basis a ‘No Observed Effect Level’ (NOEL) could not be established.
The change observed at a target dose concentration of 50 mg/m3 was considered not to be indicative of a serious adverse effect of treatment and on this basis may be regarded as a “No Observed Adverse Effect Level” (NOAEL). - Executive summary:
In this study, OS80020 (product as manufactured diluted to 65% in mineral oil) was administered to assess the toxic effects by inhalation of the test item as an aerosol to 30 rats (5/sex/group) for 6 hours per day, 5 days per week for 4 weeks at target concentrations of 50, 150 and 250 milligrams aerosol per cubic meter of air (mg/m3). Control animals (5/sex) received; air only, while in chamber.
Exposures were initiated on 27 October 1986 and were completed on 21 November 1986. Exposure levels were monitored gravimetrically four, times per chamber per day. Particle size distribution measurements were made once each week using a Delron DCI-6 Cascade Impactor.
Physical observations for abnormal signs were made during exposure for all animals. Detailed physical examinations were conducted weekly on all animals. Body weight measurements were recorded weekly and once during the pre test period, on Test Day 1; body weight measurements were also obtained just prior to sacrifice on Test Day 29. Just prior to sacrifice, blood samples were obtained for haematology and clinical chemistry then all animals were sacrificed, selected organs were weighed and organ/body weight ratios were calculated. A complete gross post mortem examination was conducted on all animals followed by microscopic examination of selected tissues.
The cumulative mean analytical exposure concentrations as determined gravimetrically were 49.5, 156 and 260 mg/m3 OS80020, with an average nominal concentration of 272, 1060 and 1360 mg/m3OS80020 for the low, mid and high dose groups, respectively. Particle size distribution determinations indicated the test aerosol atmosphere was respirable to the rat.
All animals survived the duration of the study.
Physical observations during the exposures included red nasal discharge, matted coat and decreased activity at the two higher levels.
No significant respiratory signs were noted during the weekly observations; however increased incidence of dried red nasal discharge and matted coat was seen among the treated animals.
Body weight measurements indicated a trend towards lower weight gain, especially in the high level males. However, this difference was not statistically significant.
Haematology and clinical chemistry parameters were generally not indicative of any test-material effect.
Terminal organ weight and organ body weight ratios were clearly indicative of a respiratory effect with significant dose related increases in lung weights and ratios at the mid and high levels. Other organ weights and ratios were unremarkable.
Gross post mortem evaluations were unremarkable. However, a higher incidence was seen microscopically in, the mid and high level lungs of accumulation of intra alveolar macrophages and hyperplasia/hypertrophy of bronchiole epithelium. Other microscopic findings were not considered test-article related.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.